AstraZeneca Seeking Patient Investors: Pipeline Holds Promise, But Long-Term
AstraZeneca’s mid-stage pipeline includes several interesting assets, particularly in oncology, and the company is determined to accelerate development of key projects under CEO Soriot’s turn-around plan. But even if the R&D team successfully executes on faster development timelines, the reward for investors is years away.
You may also be interested in...
NDA and BLA submission news from our US FDA Performance Tracker.
The big pharma denies reports it is disbanding antibiotics research, but says it is continuing to explore partnering opportunities for its non-core portfolio, including infectious disease.
Salix and Progenics’ appeal of FDA’s “complete response” letter for Relistor argues that potential safety issues for the opioid-induced constipation claim could be handled in a post-marketing study.